2021
DOI: 10.2217/fon-2020-1131
|View full text |Cite
|
Sign up to set email alerts
|

Additional Adjuvant Capecitabine in Early Breast Cancer Patients: A Meta-Analysis of Randomized Controlled Trials

Abstract: Aims: To assess the efficacy and safety of adjuvant capecitabine in early breast cancer patients. Methods: A literature search of databases was conducted to identify randomized controlled trials reporting the efficacy and toxicity of capecitabine as adjuvant therapy in early breast cancer patients. Results: Six studies were eligible and included a total of 6941 patients. Disease-free survival (hazard ratio = 0.79; 95% CI = 0.71–0.88; p < 0.0001) was significantly improved with additional capecitabine, where… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 31 publications
0
1
0
Order By: Relevance
“…Substantial survival benefits of adjuvant capecitabine therapy for early-stage TNBC have been demonstrated in previous literature [ 10 , 14 , 16 ]. The evidence of its cost-effectiveness is a pivotal consideration for treatment decision-making in developing countries, especially for those with limited health resources.…”
Section: Discussionmentioning
confidence: 96%
“…Substantial survival benefits of adjuvant capecitabine therapy for early-stage TNBC have been demonstrated in previous literature [ 10 , 14 , 16 ]. The evidence of its cost-effectiveness is a pivotal consideration for treatment decision-making in developing countries, especially for those with limited health resources.…”
Section: Discussionmentioning
confidence: 96%
“…Focusing on the association of capecitabine and early TNBC, there were two meta-analyses recently (18,19). However, meta-analysis from Xun et al did not extract data from the TACT2 trial, which should be included as well (14,18).…”
Section: Discussionmentioning
confidence: 99%
“…In addition, the GAIN and GEICAM/2003-10 trials only consisted node-positive patients; in other words, they should be incorporated to the nodal status subgroup analysis as well (13, 15). Zhou et al included trials more rigorously, so subgroup analysis performed with less information (19).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation